Information de reference pour ce titreAccession Number: | 00078401-201712000-00002.
|
Author: | Hu, Longbo a, c; Li, Jinqian b; Cai, Hua c; Yao, Wenxia d; Xiao, Jing c; Li, Yi-Ping b; Qiu, Xiu a, **; Xia, Huimin a, e, ***; Peng, Tao c, *
|
Institution: | (a) Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China (b) Institute of Human Virology and Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China (c) State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou, 511436, China (d) The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China (e) Department of Neonatal Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China
|
Title: | |
Source: | Antiviral Research. 148:5-14, December 2017.
|
Abstract: | Direct-acting antivirals (DAAs), which target hepatitis C virus (HCV) proteins, have exhibited impressive efficacy in the management of chronic hepatitis C. However, the concerns regarding high costs, drug resistance mutations and subsequent unexpected side effects still call for the development of host-targeting agents (HTAs) that target host factors involved in the viral life cycle and exhibit pan-genotypic antiviral activity. Given the close relationship between lipid metabolism and the HCV life cycle, we investigated the anti-HCV activity of a series of lipid-lowering drugs that have been approved by government administrations or proven safety in clinical trials. Our results showed that avasimibe, an inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT), exhibited marked pan-genotypic inhibitory activity and superior inhibition against HCV when combined with DAAs. Moreover, avasimibe significantly impaired the assembly of infectious HCV virions. Mechanistic studies demonstrated that avasimibe induced downregulation of microsomal triglyceride transfer protein expression, resulting in reduced apolipoprotein E and apolipoprotein B secretion. Therefore, the pan-genotypic antiviral activity and clinically proven safety endow avasimibe exceptional potential as a candidate for combination therapy with DAAs. In addition, the discovery of the antiviral properties of ACAT inhibitors also suggests that inhibiting the synthesis of cholesteryl esters might be an additional target for the therapeutic intervention for chronic HCV infection.
Highlights:
* We tested the anti-HCV activity of candidate lipid-lowering drugs that have been proven safety in clinical trials.
* Avasimibe, an inhibitor of ACAT, exhibited pan-genotypic inhibitory activity and high potency when combined with DAAs.
* Avasimibe interferes with HCV virion assembly by downregulating MTTP expression to inhibit the secretion of ApoE and ApoB.
* Pan-genotypic inhibitory activity and good safety profile endow avasimibe with great potential as a novel anti-HCV drug.
(C) 2017Elsevier, Inc.
|
Author Keywords: | HCV; Avasimibe; Lipid-lowering drug; ACAT; Antiviral activity; Host-targeting agents.
|
References: | Agnello, V., Abel, G., Elfahal, M., Knight, G.B., Zhang, Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 1999;96:12766-12771.
Barter, P.J., Rye, K.A. New era of lipid-lowering drugs. Pharmacol. Rev. 2016;68:458-475.
Bartosch, B., Dubuisson, J., Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 Envelope protein complexes. J. Exp. Med. 2003;197:633-642.
Baugh, J.M., Garcia-Rivera, J.A., Gallay, P.A. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antivir. Res. 2013;100:555-561.
Boyer, A., Dumans, A., Beaumont, E., Etienne, L., Roingeard, P., Meunier, J.C. The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles. J. Biol. Chem. 2014;289:18904-18913.
Buti, M., Esteban, R. Management of direct antiviral agent failures. Clin. Mol. Hepatol. 2016;22:432-438.
Cai, H., Yao, W., Li, L., Li, X., Hu, L., Mai, R., Peng, T. Cell-death-inducing DFFA-like effector B contributes to the assembly of hepatitis C virus (HCV) particles and interacts with HCV NS5A. Sci. Rep. 2016;6:27778.
Carter, W., Connelly, S., Struble, K. Reinventing HCV treatment: past and future perspectives. J. Clin. Pharmacol. 2017;57:287-296.
Chang, K.S., Jiang, J., Cai, Z., Luo, G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 2007;81:13783-13793.
Chen, S.L., Morgan, T.R. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 2006;3:47-52.
Cignarella, A., Engel, T., von Eckardstein, A., Kratz, M., Lorkowski, S., Lueken, A., Assmann, G., Cullen, P. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis. 2005;179:229-236.
Clark, P.J., Thompson, A.J., Vock, D.M., Kratz, L.E., Tolun, A.A., Muir, A.J., McHutchison, J.G., Subramanian, M., Millington, D.M., Kelley, R.I., Patel, K. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012;56:49-56.
De Re, V. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Hepat. Mon. 2010;10:231-232.
El Kassas, M., Elbaz, T., Hafez, E., Esmat, G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin. Drug Saf. 2016;15:1643-1652.
Esposito, I., Trinks, J., Soriano, V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin. Drug Metab. Toxicol. 2016;12:1197-1209.
Falcon, V., Acosta-Rivero, N., Gonzalez, S., Duenas-Carrera, S., Martinez-Donato, G., Menendez, I., Garateix, R., Silva, J.A., Acosta, E., Kouri, J. Ultrastructural and biochemical basis for hepatitis C virus morphogenesis. Virus Genes. 2017;53:151-164.
Gastaminza, P., Cheng, G., Wieland, S., Zhong, J., Liao, W., Chisari, F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008;82:2120-2129.
Grassi, G., Di Caprio, G., Fimia, G.M., Ippolito, G., Tripodi, M., Alonzi, T. Hepatitis C virus relies on lipoproteins for its life cycle. World J. Gastroenterol. WJG. 2016;22:1953-1965.
Herker, E., Harris, C., Hernandez, C., Carpentier, A., Kaehlcke, K., Rosenberg, A.R., Farese, R.V. Jr, Ott, M. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat. Med. 2010;16:1295-1298.
Hooper, A.J., Burnett, J.R., Watts, G.F. Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. Circ. Res. 2015;116:193-205.
Hu, L., Yao, W., Wang, F., Rong, X., Peng, T. GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion. PLoS One. 2014;9:e90553.
Huang, H., Sun, F., Owen, D.M., Li, W., Chen, Y., Gale, M. Jr, Ye, J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2007;104:5848-5853.
Huttunen, H.J., Havas, D., Peach, C., Barren, C., Duller, S., Xia, W., Frosch, M.P., Hutter-Paier, B., Windisch, M., Kovacs, D.M. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J. Neuropathol. Exp. Neurol. 2010;69:777-788.
Huttunen, H.J., Peach, C., Bhattacharyya, R., Barren, C., Pettingell, W., Hutter-Paier, B., Windisch, M., Berezovska, O., Kovacs, D.M. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2009;23:3819-3828.
Insull, W. Jr, Koren, M., Davignon, J., Sprecher, D., Schrott, H., Keilson, L.M., Brown, A.S., Dujovne, C.A., Davidson, M.H., McLain, R., Heinonen, T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 2001;157:137-144.
Jackel-Cram, C., Babiuk, L.A., Liu, Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 2007;46:999-1008.
Kattakuzhy, S., Levy, R., Rosenthal, E., Tang, L., Wilson, E., Kottilil, S. Hepatitis C genotype 3 disease. Hepatol. Int. 2016;10:861-870.
Krause, B.R., Anderson, M., Bisgaier, C.L., Bocan, T., Bousley, R., DeHart, P., Essenburg, A., Hamelehle, K., Homan, R., Kieft, K., et al. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J. Lipid Res. 1993;34:279-294.
Li, G., De Clercq, E. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antivir. Res. 2017;142:83-122.
Li, Y.P., Ramirez, S., Gottwein, J.M., Scheel, T.K., Mikkelsen, L., Purcell, R.H., Bukh, J. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc. Natl. Acad. Sci. U. S. A. 2012;109:E1101-E1110.
Li, Y.P., Ramirez, S., Humes, D., Jensen, S.B., Gottwein, J.M., Bukh, J. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology. 2014;146:812-821 e814.
Li, Y.P., Ramirez, S., Jensen, S.B., Purcell, R.H., Gottwein, J.M., Bukh, J. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc. Natl. Acad. Sci. U. S. A. 2012;109:19757-19762.
Liefhebber, J.M., Hague, C.V., Zhang, Q., Wakelam, M.J., McLauchlan, J. Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus. J. Biol. Chem. 2014;289:21276-21288.
Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110-113.
Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., Barnes, E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87.
Nahmias, Y., Goldwasser, J., Casali, M., van Poll, D., Wakita, T., Chung, R.T., Yarmush, M.L. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology. 2008;47:1437-1445.
Nielsen, S.U., Bassendine, M.F., Burt, A.D., Martin, C., Pumeechockchai, W., Toms, G.L. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 2006;80:2418-2428.
Ohshiro, T., Matsuda, D., Sakai, K., Degirolamo, C., Yagyu, H., Rudel, L.L., Omura, S., Ishibashi, S., Tomoda, H. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler., Thromb., Vasc. Biol. 2011;31:1108-1115.
Pawlotsky, J.M. What are the pros and cons of the use of host-targeted agents against hepatitis C? Antivir. Res. 2014;105:22-25.
Pawlotsky, J.M., Flisiak, R., Sarin, S.K., Rasenack, J., Piratvisuth, T., Chuang, W.L., Peng, C.Y., Foster, G.R., Shah, S., Wedemeyer, H., Hezode, C., Zhang, W., Wong, K.A., Li, B., Avila, C., Naoumov, N.V. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology. 2015;62:1013-1023.
Popescu, C.I., Riva, L., Vlaicu, O., Farhat, R., Rouille, Y., Dubuisson, J. Hepatitis C virus life cycle and lipid metabolism. Biology. 2014;3:892-921.
Ramirez, S., Li, Y.P., Jensen, S.B., Pedersen, J., Gottwein, J.M., Bukh, J. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology. 2014;59:395-407.
Read, S.A., Tay, E.S., Shahidi, M., George, J., Douglas, M.W. Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. J. General Virol. 2014;95:1900-1910.
Reiss, S., Rebhan, I., Backes, P., Romero-Brey, I., Erfle, H., Matula, P., Kaderali, L., Poenisch, M., Blankenburg, H., Hiet, M.S., Longerich, T., Diehl, S., Ramirez, F., Balla, T., Rohr, K., Kaul, A., Buhler, S., Pepperkok, R., Lengauer, T., Albrecht, M., Eils, R., Schirmacher, P., Lohmann, V., Bartenschlager, R. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe. 2011;9:32-45.
Sahi, J., Milad, M.A., Zheng, X., Rose, K.A., Wang, H., Stilgenbauer, L., Gilbert, D., Jolley, S., Stern, R.H., LeCluyse, E.L. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. 2003;306:1027-1034.
Sahi, J., Stern, R.H., Milad, M.A., Rose, K.A., Gibson, G., Zheng, X., Stilgenbauer, L., Sadagopan, N., Jolley, S., Gilbert, D., LeCluyse, E.L. Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo. Drug Metab. Dispos. Biol. Fate Chem. 2004;32:1370-1376.
Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R.M., Acali, S., Filocamo, G., Traboni, C., Nicosia, A., Cortese, R., Vitelli, A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002;21:5017-5025.
Scheel, T.K., Rice, C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013;19:837-849.
Shelness, G.S., Sellers, J.A. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 2001;12:151-157.
Suzuki, T. Assembly of hepatitis C virus particles. Microbiol. Immunol. 2011;55:12-18.
Suzuki, T. Morphogenesis of infectious hepatitis C virus particles. Front. Microbiol. 2012;3:38.
Thrift, A.P., El-Serag, H.B., Kanwal, F. Global epidemiology and burden of HCV infection and HCV-related disease. Nature reviews. Gastroenterol. Hepatol. 2017;14:122-132.
van der Ree, M.H., van der Meer, A.J., de Bruijne, J., Maan, R., van Vliet, A., Welzel, T.M., Zeuzem, S., Lawitz, E.J., Rodriguez-Torres, M., Kupcova, V., Wiercinska-Drapalo, A., Hodges, M.R., Janssen, H.L., Reesink, H.W. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antivir. Res. 2014;111:53-59.
Villareal, V.A., Rodgers, M.A., Costello, D.A., Yang, P.L. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses. Antivir. Res. 2015;124:110-121.
Wang, H., Perry, J.W., Lauring, A.S., Neddermann, P., De Francesco, R., Tai, A.W. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. Gastroenterology. 2014;146:1373-1385. e1371-1311.
Waris, G., Felmlee, D.J., Negro, F., Siddiqui, A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 2007;81:8122-8130.
Wilcox, L.J., Barrett, P.H., Newton, R.S., Huff, M.W. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler., Thromb., Vasc. Biol. 1999;19:939-949.
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., Yan, C., Wang, L., Chang, C.C., Chang, T.Y., Zhang, T., Zhou, P., Song, B.L., Liu, W., Sun, S.C., Liu, X., Li, B.L. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531:651-655.
Zeisel, M.B., Crouchet, E., Baumert, T.F., Schuster, C. Host-targeting agents to prevent and cure hepatitis C virus infection. Viruses. 2015;7:5659-5685.
|
Language: | English.
|
Document Type: | Articles.
|
Journal Subset: | Clinical Medicine. Pharmacology.
|
ISSN: | 0166-3542
|
DOI Number: | https://dx.doi.org/10.1016/j.ant...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|